MX2009006672A - Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol. - Google Patents
Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.Info
- Publication number
- MX2009006672A MX2009006672A MX2009006672A MX2009006672A MX2009006672A MX 2009006672 A MX2009006672 A MX 2009006672A MX 2009006672 A MX2009006672 A MX 2009006672A MX 2009006672 A MX2009006672 A MX 2009006672A MX 2009006672 A MX2009006672 A MX 2009006672A
- Authority
- MX
- Mexico
- Prior art keywords
- topiramate
- ondansetron
- alcohol consumption
- combined effects
- drugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona con el uso de combinaciones de fármacos para el tratamiento de trastornos adictivos. En forma más específica, la presente invención se relaciona con el uso de drogas junto con la intervención conductual para tratar enfermedades y trastornos relacionados con el alcohol así como para el tratamiento de la obesidad y la regulación del peso corporal.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87566806P | 2006-12-19 | 2006-12-19 | |
US89852807P | 2007-01-31 | 2007-01-31 | |
US93103107P | 2007-05-21 | 2007-05-21 | |
PCT/US2007/088100 WO2008077092A2 (en) | 2006-12-19 | 2007-12-19 | Combined effects of topiramate and ondansetron on alcohol consumption |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009006672A true MX2009006672A (es) | 2009-10-26 |
Family
ID=39537067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009006672A MX2009006672A (es) | 2006-12-19 | 2007-12-19 | Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol. |
Country Status (8)
Country | Link |
---|---|
US (1) | US20100041689A1 (es) |
EP (2) | EP2124909A4 (es) |
JP (1) | JP2010513569A (es) |
AU (1) | AU2007333656A1 (es) |
CA (1) | CA2673481A1 (es) |
CR (1) | CR10938A (es) |
MX (1) | MX2009006672A (es) |
WO (1) | WO2008077092A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2677205A1 (en) * | 2007-01-31 | 2008-08-07 | University Of Virginia Patent Foundation | Topiramate plus naltrexone for the treatment of addictive disorders |
CA2697990A1 (en) * | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
US8697361B2 (en) | 2008-02-28 | 2014-04-15 | University Of Virginia Patent Foundation | Serotonin transporter gene and treatment of alcoholism |
US9226918B2 (en) | 2008-12-04 | 2016-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating or preventing narcotic withdrawal symptoms |
KR20120101588A (ko) * | 2010-01-07 | 2012-09-13 | 비버스 인크. | 탄산탈수효소 억제제 및 추가적인 활성제의 조합에 의한 폐쇄 수면 무호흡 증후군의 치료 |
LT2801625T (lt) | 2010-07-02 | 2018-03-12 | University Of Virginia Patent Foundation | Molekulinis genetinis būdas, skirtas priklausomybės nuo alkoholio ir narkotikų gydymui ir diagnozavimui |
US20130072516A1 (en) * | 2011-09-07 | 2013-03-21 | Eagle Advancement Institute Llc | Method of alcohol cessation and treatment |
US20130096173A1 (en) * | 2011-09-09 | 2013-04-18 | Bankole A. Johnson | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
WO2014152207A1 (en) | 2013-03-15 | 2014-09-25 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
US11528924B2 (en) | 2014-12-09 | 2022-12-20 | Clearmind Medicine, Inc. | Alcoholic beverage substitutes |
EP3705469A1 (en) | 2014-12-09 | 2020-09-09 | GOLAN, Ezekiel | Binge behavior regulators |
WO2016154028A1 (en) | 2015-03-26 | 2016-09-29 | Iversen Jacqueline M | Methods and compositions to inhibit symptoms associated with veisalgia |
US11865112B2 (en) | 2018-11-06 | 2024-01-09 | Purdue Pharma L.P. | Compositions and methods for opioid antagonist delivery |
AU2020264769A1 (en) * | 2019-05-02 | 2021-12-23 | Closed Loop Medicine Ltd | Methods and systems for providing personalised medicine to a patient |
US20220117916A1 (en) * | 2020-10-19 | 2022-04-21 | SafeRx Pharmaceuticals, LLC | Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA974518A (en) | 1972-04-20 | 1975-09-16 | Merz And Co. | Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US5550021A (en) * | 1990-02-07 | 1996-08-27 | Board Of Regents, The University Of Texas System | Allelic diagnosis of susceptibility to compulsive disorder |
DE4010079A1 (de) | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
EP0714663A3 (en) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
EP0945133A1 (en) * | 1998-03-26 | 1999-09-29 | Lipha | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator |
US6200604B1 (en) | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
US20040167164A1 (en) * | 1998-05-05 | 2004-08-26 | Jose Pozuelo | Compositions and methods for treating particular chemical addictions and mental illnesses |
US6287765B1 (en) * | 1998-05-20 | 2001-09-11 | Molecular Machines, Inc. | Methods for detecting and identifying single molecules |
SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
AU779248B2 (en) * | 1999-02-24 | 2005-01-13 | University Of Cincinnati, The | Use of sulfamate derivatives for treating impulse control disorders |
WO2002026118A2 (en) * | 2000-09-29 | 2002-04-04 | New Health Sciences, Inc. | Systems and methods for assessing vascular effects of a treatment |
US7122308B2 (en) * | 2001-02-16 | 2006-10-17 | Centre For Addiction And Mental Health | Detection of antidepressant induced mania |
US7033771B2 (en) * | 2001-05-08 | 2006-04-25 | Takeda Pharmaceutical Company Limited | Use of insulin response modulators in the treatment of diabetes and insulin resistance |
EP1262196A3 (en) * | 2001-05-23 | 2002-12-18 | Pfizer Products Inc. | Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence |
HUP0401022A3 (en) * | 2001-08-14 | 2006-11-28 | Biotie Therapies Corp | Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse |
US20030100479A1 (en) * | 2001-08-21 | 2003-05-29 | Dow David J. | Gene polymorphisms and response to treatment |
US20060173064A1 (en) | 2001-08-24 | 2006-08-03 | Lippa Arnold S | (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders |
AU2002348135A1 (en) * | 2001-10-31 | 2003-05-12 | Recovery Pharmaceuticals, Inc. | Methods for the treatment of addiction |
WO2004096201A1 (en) | 2003-04-29 | 2004-11-11 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
GB0316915D0 (en) * | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
US7163969B2 (en) * | 2003-10-14 | 2007-01-16 | Stockhausen, Inc. | Superabsorbent polymer aqueous paste and coating |
US20050245461A1 (en) * | 2004-03-19 | 2005-11-03 | Elliot Ehrich | Methods for treating alcoholism |
CN2722428Y (zh) | 2004-07-21 | 2005-08-31 | 上海正贝照明电器有限公司 | 镇流器内藏式一体化节能灯 |
PL1928438T3 (pl) * | 2005-09-26 | 2013-08-30 | Avigen Inc | Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających |
US20070292880A1 (en) * | 2006-05-05 | 2007-12-20 | Robert Philibert | Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome |
US20080004260A1 (en) * | 2006-06-29 | 2008-01-03 | Transcept Pharmaceuticals, Inc. | Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions |
US7645750B2 (en) * | 2006-12-13 | 2010-01-12 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Method of treating symptoms of hormonal variations |
CA2677205A1 (en) * | 2007-01-31 | 2008-08-07 | University Of Virginia Patent Foundation | Topiramate plus naltrexone for the treatment of addictive disorders |
US20080228698A1 (en) * | 2007-03-16 | 2008-09-18 | Expanse Networks, Inc. | Creation of Attribute Combination Databases |
WO2009026381A2 (en) * | 2007-08-21 | 2009-02-26 | University Of Virginia Patent Foundation | Method, computer program product and system for individual assessment of alcohol sensitivity |
CA2697990A1 (en) * | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
US8697361B2 (en) * | 2008-02-28 | 2014-04-15 | University Of Virginia Patent Foundation | Serotonin transporter gene and treatment of alcoholism |
GB2474146B (en) * | 2008-04-29 | 2013-04-10 | Nodality Inc | Methods of determining the health status of an individual |
US20120115149A1 (en) * | 2009-05-01 | 2012-05-10 | University Of Virginia Patent Foundation | Serotonin transporter gene and treatment of alcoholism |
-
2007
- 2007-12-19 CA CA002673481A patent/CA2673481A1/en not_active Abandoned
- 2007-12-19 EP EP07869501A patent/EP2124909A4/en not_active Withdrawn
- 2007-12-19 EP EP12170027A patent/EP2556830A1/en not_active Withdrawn
- 2007-12-19 AU AU2007333656A patent/AU2007333656A1/en not_active Abandoned
- 2007-12-19 WO PCT/US2007/088100 patent/WO2008077092A2/en active Application Filing
- 2007-12-19 MX MX2009006672A patent/MX2009006672A/es unknown
- 2007-12-19 JP JP2009543177A patent/JP2010513569A/ja active Pending
- 2007-12-19 US US12/520,095 patent/US20100041689A1/en not_active Abandoned
-
2009
- 2009-07-17 CR CR10938A patent/CR10938A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010513569A (ja) | 2010-04-30 |
CA2673481A1 (en) | 2008-06-26 |
WO2008077092A8 (en) | 2009-08-20 |
EP2124909A4 (en) | 2010-03-31 |
EP2124909A2 (en) | 2009-12-02 |
AU2007333656A1 (en) | 2008-06-26 |
WO2008077092A3 (en) | 2008-08-14 |
US20100041689A1 (en) | 2010-02-18 |
WO2008077092A2 (en) | 2008-06-26 |
EP2556830A1 (en) | 2013-02-13 |
CR10938A (es) | 2010-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009006672A (es) | Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol. | |
NZ620326A (en) | Cd37 immunotherapeutic combination therapies and uses thereof | |
EP2217596B8 (en) | Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 | |
WO2011083150A3 (en) | Obesity small molecules | |
AU2011328009A8 (en) | Compounds and methods for treating pain | |
TR201819564T4 (tr) | Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar. | |
AU2008232453A8 (en) | Methods and compositions for reduction of side effects of therapeutic treatments | |
GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
MX2009006339A (es) | Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide. | |
MX2010004074A (es) | Combinacion 059. | |
WO2010009478A3 (en) | Compositions and methods for treating disorders associated with overweight animals | |
MY151018A (en) | Use of nutritional compositions for preventing disorders | |
WO2007084818A3 (en) | Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
WO2009068659A3 (en) | Novel disease treatment by predicting drug association | |
WO2009020802A3 (en) | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity | |
NZ600858A (en) | Suture line administration technique using botulinum toxins | |
MX355606B (es) | Método in vitro para determinar el potencial miope de un paciente. | |
TN2010000214A1 (en) | Methods for treating obesity and obesity related diseases and disorders | |
WO2010080756A3 (en) | Harmine derivatives for reducing body weight | |
MX343326B (es) | Metodos para mejorar el metabolismo energetico. | |
WO2007135426A3 (en) | Treatment of neurodegeneratives diseases | |
MX2013011996A (es) | Metodos para regular la expresion de genes de sirtuina. | |
WO2008147483A8 (en) | Neurogenic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general |